244 related articles for article (PubMed ID: 23977189)
1. HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Nii-Trebi NI; Ibe S; Barnor JS; Ishikawa K; Brandful JA; Ofori SB; Yamaoka S; Ampofo WK; Sugiura W
PLoS One; 2013; 8(8):e71972. PubMed ID: 23977189
[TBL] [Abstract][Full Text] [Related]
2. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
[TBL] [Abstract][Full Text] [Related]
3. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
[TBL] [Abstract][Full Text] [Related]
4. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
[TBL] [Abstract][Full Text] [Related]
5. Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana.
Nii-Trebi NI; Brandful JAM; Ibe S; Sugiura W; Barnor JS; Bampoh PO; Yamaoka S; Matano T; Yoshimura K; Ishikawa K; Ampofo WK
J Med Microbiol; 2017 Nov; 66(11):1663-1672. PubMed ID: 29068286
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
[TBL] [Abstract][Full Text] [Related]
7. High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Deletsu SD; Maina EK; Quaye O; Ampofo WK; Awandare GA; Bonney EY
Medicine (Baltimore); 2020 Feb; 99(7):e18777. PubMed ID: 32049783
[TBL] [Abstract][Full Text] [Related]
8. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Luo XL; Mo LD; Su GS; Huang JP; Wu JY; Su HZ; Huang WH; Luo SD; Ni ZY
J Pharmacol Sci; 2019 Apr; 139(4):275-279. PubMed ID: 30928089
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
11. Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
Gare J; Ryan CE; David M; Timbi D; Kaima P; Kombati Z; Imara U; Kelly-Hanku A; Siba PM; Crowe SM; Hearps AC
J Antimicrob Chemother; 2014 Aug; 69(8):2183-6. PubMed ID: 24722838
[TBL] [Abstract][Full Text] [Related]
12. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
13. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Mendoza Y; Castillo Mewa J; Martínez AA; Zaldívar Y; Sosa N; Arteaga G; Armién B; Bautista CT; García-Morales C; Tapia-Trejo D; Ávila-Ríos S; Reyes-Terán G; Bello G; Pascale JM
PLoS One; 2016; 11(4):e0154317. PubMed ID: 27119150
[TBL] [Abstract][Full Text] [Related]
15. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M
BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456
[TBL] [Abstract][Full Text] [Related]
16. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
[TBL] [Abstract][Full Text] [Related]
17. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Paredes R; Cheng I; Kuritzkes DR; Tuomala RE;
AIDS; 2010 Jan; 24(1):45-53. PubMed ID: 19915448
[TBL] [Abstract][Full Text] [Related]
18. Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Weng YW; Chen IT; Tsai HC; Wu KS; Tseng YT; Sy CL; Chen JK; Lee SS; Chen YS
BMC Infect Dis; 2019 Aug; 19(1):741. PubMed ID: 31443633
[TBL] [Abstract][Full Text] [Related]
19. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
